Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$3.74 - $6.7 $2.55 Million - $4.56 Million
-681,002 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$6.05 - $10.41 $10,508 - $18,082
1,737 Added 0.26%
681,002 $4.27 Million
Q2 2021

Aug 13, 2021

BUY
$6.66 - $10.92 $57,236 - $93,846
8,594 Added 1.28%
679,265 $6.7 Million
Q1 2021

May 14, 2021

SELL
$4.59 - $18.74 $1.89 Million - $7.73 Million
-412,453 Reduced 38.08%
670,671 $6.26 Million
Q4 2020

Feb 12, 2021

BUY
$3.93 - $5.5 $706,224 - $988,355
179,701 Added 19.89%
1,083,124 $5.2 Million
Q3 2020

Nov 13, 2020

BUY
$4.01 - $5.56 $548,395 - $760,368
136,757 Added 17.84%
903,423 $3.62 Million
Q2 2020

Aug 14, 2020

SELL
$3.0 - $5.52 $52,776 - $97,107
-17,592 Reduced 2.24%
766,666 $3.52 Million
Q1 2020

May 15, 2020

BUY
$2.54 - $4.75 $277,251 - $518,481
109,154 Added 16.17%
784,258 $2.56 Million
Q4 2019

Feb 14, 2020

BUY
$2.83 - $4.61 $15,434 - $25,142
5,454 Added 0.81%
675,104 $2.91 Million
Q3 2019

Nov 14, 2019

SELL
$3.83 - $4.72 $136,271 - $167,937
-35,580 Reduced 5.05%
669,650 $2.64 Million
Q2 2019

Aug 14, 2019

BUY
$3.71 - $4.83 $2.62 Million - $3.41 Million
705,230 New
705,230 $3.28 Million

Others Institutions Holding CDXC

About ChromaDex Corp.


  • Ticker CDXC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,350,896
  • Market Cap $362M
  • Description
  • ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...
More about CDXC
Track This Portfolio

Track Uniplan Investment Counsel, Inc. Portfolio

Follow Uniplan Investment Counsel, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Uniplan Investment Counsel, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Uniplan Investment Counsel, Inc. with notifications on news.